- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
Company Profile
Introduction to Chongqing Pharmaceutical Industry Research Institute Co., Ltd.
Chongqing Pharmaceutical Industry Research Institute was established in 1950 and is a high-tech enterprise mainly engaged in the research and development of chemical drugs in the southwest region. In 2001, as one of the first batch of restructured research institutes in Chongqing, it was jointly established by Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. and Chongqing Huayi Holdings (Group) Co., Ltd. as Chongqing Pharmaceutical Industry Research Institute Co., Ltd. (hereinafter referred to as "Chongqing Medical Institute"). In September 2019, Chongqing Yaoyou Pharmaceutical Co., Ltd. became the wholly-owned subsidiary of Chongqing Medical Institute.
After decades of development, Chongqing Medical Institute has established a complete and standardized drug research and development system, including innovative drug development, synthetic process research, formulation process research, analytical methodology research, and pharmacological and toxicological evaluation. In line with the continuous development of the pharmaceutical industry and the demand for innovative research and development, in April 2019, the Medical Institute relocated to the Liangjiang High-end Biopharmaceutical Industrial Park in Jiangbei, leveraging the resource advantages of the Yaoyou industry to promote the gradual transformation of the Medical Institute from imitation to innovation.
Chongqing Medical Institute has a registered capital of 55 million yuan, with more than 100 employees, over 70 various R&D professional technical personnel, 70% of whom have a bachelor's degree or above, and an average age of 36.
The total area of laboratories used for R&D at Chongqing Medical Institute exceeds 7,000 square meters, equipped with internationally advanced analytical testing equipment, and has more than 1,000 various instruments and devices.
In the past decade, more than 270 Chinese invention patents, 24 PCT patents, and 37 foreign patents have been applied for, with 76 Chinese patent authorizations and 20 foreign patent authorizations obtained.
In the past twenty years, more than 200 national key projects such as the "Seventh Five-Year Plan", "Eighth Five-Year Plan", "863" program, and key projects of Chongqing City have been completed, winning more than 30 national and provincial-level scientific and technological achievement awards, and undertaking 7 major new drug creation projects of the national "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan", as well as 1 national major scientific and technological achievement transformation project. Over 80% of the scientific research results have been transformed into productive forces, creating an industrial output value of over 10 billion yuan, achieving significant social and economic benefits.
Chongqing Medical Institute has been recognized as a national high-tech enterprise, a national enterprise technology center (affiliated with Fosun Pharmaceutical), a national intellectual property advantage enterprise, an innovative enterprise in Chongqing, a chemical pharmaceutical engineering technology research center in Chongqing, a new drug delivery system engineering technology research center in Chongqing, and a postdoctoral research workstation in Chongqing.
Facing future opportunities and challenges, Chongqing Medical Institute will uphold the corporate spirit of "Cooperation, Professionalism, Responsibility, Innovation", adhere to the main line of creating new drugs with independent intellectual property rights, and implement talent strategies, innovation strategies, and internationalization strategies. By building a characteristic technology platform for new drug R&D, establishing a balanced and standardized new drug research and development system and industrialization trial implementation system recognized by the international mainstream market, it aims to construct a high-tech enterprise driven by pharmaceutical technology R&D that is of high quality domestically and aligned with international standards.
Company address: No. 565 Tushan Road, Nan'an District, Chongqing City, Postal Code: 400061, Contact number:023-62513495Fax:023-62512066Company website:www.cpri.com.cnE-mail:cpri@cpri.com.cn
Contact
Tel: 86-023-62505956
E-mail: cpri@cpri.com.cn
Scan mobile websites
